Hainan Shuangcheng Pharmaceutical (002693.SZ) announced that it had inked letters of intent to but equity in two pharmaceutical companies from two Germans.
Shuangcheng Pharmaceutical mulls to buy a 74.9 percent stake in Lyomark Pharma GmbH and Bendalis GmbH from the two Germans for approximately 70-200 million yuan, according to a company filing with the Shenzhen Stock Exchange. Lyomark is a supplier in pharmaceutical ingredient, preparation and R&D chemicals which has total assets of 6.6 million euros by the end of 2014.
Bendalis specializes in developing and promoting high-tech generics and patent cancer drugs which had total assets of 2.8 million euros by the end of 2014.
Latest comments